Sotac Pharmaceuticals Ltd Financials
Company Logo

Sotac Pharmaceuticals Ltd Financial Statement

Sotac Pharmaceuticals Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Sep 2024
Revenue18.09
Operating Expense16.09
Net Profit0.86
Net Profit Margin4.75
Earning Per Share0.78
EBIDTA2.03
Effective Tax Rate16.50

Sotac Pharmaceuticals Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Total Revenue Annual62.38
Operating Expenses Annual54.70
Operating Profit Annual10.06
Interest Annual1.17
Depreciation2.47
Net Profit Annual4.77
Tax Annual1.64

Sotac Pharmaceuticals Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Cash Flow at the Beginning0.64
Cash Flow from Operations-6.08
Cash Flow from Investing-1.89
Cash Flow from Financing7.78
Cash Flow at the End0.45

Sotac Pharmaceuticals Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
PBDIT Margin (%)16.13
PBIT Margin (%)12.17
PBT Margin (%)1.78
Net PROFIT Margin (%)7.65
Return On Networth / Equity (%)9.42
Return On Networth /Employed (%)11.41
Return On Assets (%)7.19
Total Debt / Equity (X)0.31
Asset Turnover Ratio (%)0.94

Sotac Pharmaceuticals Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Fixed Assets Annual16.66
Total Current Assets Annual54.90
Non Current Assets Annual30.40
Total Shareholders Funds Annual53.03
Total Assets Annual85.29

Sotac Pharmaceuticals Ltd Earning Calls

EPS (INR)

Expected

0.42

Reported

0.42

Surprise

0.00%

Jun 2024

EPS beaten by 0.00%

Mar 2024

EPS beaten by 0.76%

Dec 2023

EPS beaten by 0.68%

FAQS on Sotac Pharmaceuticals Ltd Financials

As of Oct 20, 2025, Sotac Pharmaceuticals Ltd has a market capitalization of 131.22 Cr. Value Research classifies it as a Micro-Cap company.

Yes, Sotac Pharmaceuticals Ltd is with a debt-to-equity ratio of 0.38.

In FY 2024 , Sotac Pharmaceuticals Ltd recorded a total revenue of approximately 62.38 Cr marking a significant milestone in the company's financial performance.

Sotac Pharmaceuticals Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately Infinity% and 0.0% annually, respectively..

Sotac Pharmaceuticals Ltd's current PE ratio is 27.51.

Sotac Pharmaceuticals Ltd's ROCE averaged 15.6% from the FY ending March 2023 to 2025, with a median of 14.8%. It peaked at 21.6% in March 2023, reflecting strong capital efficiency over the period..

Sotac Pharmaceuticals Ltd's latest EBIT is Rs. 7.58 Cr, surpassing the average EBIT of Rs. 7.72 Cr over the 5 years..

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions